Prostate Cell News Volume 9.41 | Oct 26 2018

TOP STORY

New Kind of Compound Shows Early Promise Against Prostate Cancer

A joint research team from NYU School of Medicine and New York University found that their “cyclic peptoids” reduced the growth of prostate cancer cells in cultures by 95 percent compared to untreated cells. The experimental drugs also blocked a key, related growth signal in live animal tests. [Press release from NYU Langone Hospitals discussing online prepublication in Nature Communications] Press Release | Full Article | Editorial

(Ranked by impact factor of the journal)

Heterozygous Deletion of Chromosome 17p Renders Prostate Cancer Vulnerable to Inhibition of RNA Polymerase II

Scientists discovered that heterozygous loss of 17p confered a selective dependence of castration-resistant prostate cancer cells on the ubiquitin E3 ligase Ring-Box 1 (RBX1). RBX1 activated POLR2A by the K63-linked ubiquitination and thus elevated RNA polymerase II-mediated mRNA synthesis. [Nat Commun] Full Article

Adipose Stromal Cell Targeting Suppresses Prostate Cancer Epithelial-Mesenchymal Transition and Chemoresistance

By using human cell co-culture models, investigators demonstrated that adipose stromal cells (ASCs) induced epithelial-mesenchymal transition in prostate cancer cells. They demonstrated that ASC interaction rendered cancer cells more migratory and resistant to docetaxel, cabazitaxel, and cisplatin chemotherapy. [Oncogene] Abstract

Communication of Prostate Cancer Cells with Bone Cells via Extracellular Vesicle RNA; a Potential Mechanism of Metastasis

Researchers demonstrated that prostate cancer (PCa) cell extracellular vesicles (EVs) both enhanced osteoblast viability and produced a significantly more supportive growth environment for PCa cells when grown in co-culture with EV-treated osteoblasts. [Oncogene] Full Article

Cytoplasmic FLIP(S) and Nuclear FLIP(L) Mediate Resistance of Castrate-Resistant Prostate Cancer to Apoptosis Induced by IAP Antagonists

In the presence of recombinant or macrophage-derived tumor necrosis factor-α, scientists found that inhibitor of apoptosis protein (IAP) antagonists triggered degradation of cIAP1 and induced formation of Complex-IIb, consisting of caspase-8, FADD and RIPK1 in castration-resistant prostate cancer models; however, no, or modest levels of apoptosis were induced. [Cell Death Dis] Full Article

Angiotensin 1-7 Modulates Molecular and Cellular Processes Central to the Pathogenesis of Prostate Cancer

The authors indicate that while angiotensin 1-7 could effectively reduce cell proliferation in DU-145, it could induce a significant decrease in the expression of MKI67 in LNCaP. In both cell lines they also observed a reduction in colony size in soft agar assay. [Sci Rep] Full Article

TRPM4 Channel Is Involved in Regulating Epithelial to Mesenchymal Transition, Migration, and Invasion of Prostate Cancer Cell Lines

PC3 cells with reduced levels of transient receptor potential melastatin 4 (TRPM4) displayed a decrease of migration/invasion capability. A reduction in the expression of Snail1, a canonical epithelial to mesenchymal transition transcription factor, was also observed. [J Cell Physiol] Abstract

Combined N-Terminal Androgen Receptor and Autophagy Inhibition Increases the Antitumor Effect in Enzalutamide Sensitive and Enzalutamide Resistant Prostate Cancer Cells

Treatment with EPI-001 (EPI) resulted in a dose-dependent reduction of cell growth and increased apoptosis in both cancer cell lines on day seven. In addition, EPI treatment demonstrated an upregulated autophagosome formation in LNCaP and LNCaP-EnzR cells. [Prostate] Abstract

Lack of Combination Effects of Soy Isoflavones and Taxane Chemotherapy of Castration-Resistant Prostate Cancer

Genistein, daidzein, and equol did not affect growth of VCaP, 22Rv1, C4-2, and PC-3 castrate-resistant prostate cancer cells or growth inhibition of these cells by docetaxel and cabazitaxel. These isoflavones did not inhibit microtubule disassembly in vitro or inhibit the microtubule effects of taxanes and genistein did not bind substantially to microtubules. [Prostate] Abstract

Bitter Taste Receptors Are Expressed in Human Epithelial Ovarian and Prostate Cancers Cells and Noscapine Stimulation Impacts Cell Survival

Researchers examined the prevalence of bitter taste receptor (Tas2R) subtype expression in several epithelial ovarian or prostate cancer cell lines, and the functionality of Tas2R14 was determined. [Mol Cell Biochem] Abstract

Subscribe to one of our other 19 science newsletters such as Mammary Cell News & ESC & iPSC News.

The Importance of Targeting Intracrinology in Prostate Cancer Management

Development of additional drugs targeting major components of intracrinology is ongoing. Application of these new drugs and administration of combinations of existing drugs will ultimately lead to an increase in the efficacy of such treatments as well as to reduce the toxicity of the therapy and to prevent the risk of resistance. [World J Urol] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

Inovio Presents Progression Free Survival & PSA Doubling Time Improvements in Prostate Cancer Patients Treated with INO-5150

Inovio Pharmaceuticals, Inc. announced that new data from the company’s recently completed Phase Ib study with INO-5150 demonstrated a slowing of Prostate-Specific Antigen (PSA) Doubling Time in men with prostate cancer. [Press release from Inovio Pharmaceuticals, Inc. discussing research presented at the European Society for Medical Oncology (ESMO) 2018 Congress, Munich] Press Release

Phase III Trial of Darolutamide in Patients with Non-Metastatic Castration-Resistant Prostate Cancer Meets Primary Endpoint

The Phase III ARAMIS (Androgen Receptor inhibiting Agent for MetastatIc-free Survival) trial that investigated darolutamide in men with non-metastatic castration-resistant prostate cancer met its primary endpoint. Darolutamide significantly extended metastasis-free survival compared to placebo. [Bayer AG] Press Release

Myovant Sciences Announces Completion of Enrollment in Phase III HERO Trial of Relugolix in Men with Advanced Prostate Cancer

Myovant Sciences announced it has completed patient enrollment in its pivotal Phase III clinical trial, HERO, which is evaluating the safety and efficacy of relugolix for the treatment of men with advanced prostate cancer. [Myovant Sciences Ltd.] Press Release

Cancer Targeted Technology Receives an SBIR Grant and Announces Expansion of Its Pipeline

Cancer Targeted Technology announced that it received a Small Business Innovation Research (SBIR) grant to develop CTT1700, a unique prodrug targeted at men with prostate cancer that express Prostate Specific Membrane Antigen. [Cancer Targeted Technology] Press Release

Font of Despair: In the Fierce Competition for Science Funding, Even a Typeface Glitch Can Be Fatal

To those experienced in requesting cash from both the Department of Veterans Affairs and the National Institutes of Health, rejection on the basis of margin or serif, if not the most pressing problem in biomedical research, is unsurprising and frustrating. [STAT News] Editorial

What a Massive Database of Retracted Papers Reveals About Science Publishing’s ‘Death Penalty’

Nearly a decade ago, headlines highlighted a disturbing trend in science: The number of articles retracted by journals had increased 10-fold during the previous 10 years. Fraud accounted for some 60% of those retractions; one offender, anesthesiologist Joachim Boldt, had racked up almost 90 retractions after investigators concluded he had fabricated data and committed other ethical violations. [ScienceInsider] Editorial

First Analysis of ‘Pre-Registered’ Studies Shows Sharp Rise in Null Findings

Studies that fail to find a positive result are often filed away, never to see the light of day, which leads to a publication bias that compromises the credibility of scientific literature. An analysis now suggests that registering and peer-reviewing study protocols before research is conducted could improve this ‘file-drawer problem’, and help to correct the existing publication bias towards positive findings. [Nature News] Editorial

NEW 6^th Annual European Congress on Clinical and Translational Medicine
October 18-20, 2019
Vienna, Austria

Visit our events page to see a complete list of events in the community.

NEW Posdoctoral Position – Prostate Cancer Research (Louisiana State University Health Sciences Center)

NEW PhD Studentship – Molecular Radiooncology (German Cancer Research Center)

Group Leader – Cancer Biology and/or Therapy (Institute of Oncology Research Universita della Svizzera Italiana)

PhD Studentships – Cancer Research (The Cancer Research UK Manchester Institute)

Postdoctoral Fellow – Cancer Immunotherapy (University of Notre Dame)

Postdoctoral Fellow – Prostate Disease Research (Henry M. Jackson Foundation for the Advancement of Military Medicine)

Group Leader – Biostatistics and Systems Biology in Cancer Research (Oslo University Hospital)

Assistant/Associate/Professor – Cancer Biology (University of Cincinnati)

Postdoctoral Position – Genitourinary Cancers (Columbia University Medical Center)

Postdoctoral Position – Prostate Cancer (The University of Minnesota, Twin Cities)

Research Fellow – Prostate Cancer (Sechenov University)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.